Jena/Germany | 12 July 2018 | Carl Zeiss Meditec AG
- Effective 1 October 2018, Dr. Christian Müller, current CFO of Carl Zeiss Meditec AG, will become CFO of Carl Zeiss AG
- Justus Felix Wehmer to become new CFO of Carl Zeiss Meditec AG
- Management Board of Carl Zeiss Meditec AG to be expanded with appointment of Jan Willem de Cler
Effective 30 September 2018, Dr. Christian Müller will leave the Management Board of Carl Zeiss Meditec AG (FSE: AFX) and, on 1 October 2018, will become Chief Financial Officer (CFO) of Carl Zeiss AG. Müller has served as CFO of Carl Zeiss Meditec AG since 2009. He came to Carl Zeiss Meditec AG in 2006 where he headed the newly created Surgical Ophthalmology strategic business unit. The Supervisory Board of Carl Zeiss Meditec AG has appointed Justus Felix Wehmer as CFO of Carl Zeiss Meditec AG, also effective 1 October 2018. Mr. Wehmer is currently CFO and Co-Head of the ZEISS Microscopy business group.
In addition, effective 1 October 2018, the Management Board of Carl Zeiss Meditec AG will be expanded from two to three members with the appointment of Jan Willem de Cler. Mr. de Cler has been at ZEISS since 2004 and currently heads Surgical Ophthalmology within Carl Zeiss Meditec AG. As Member of the Management Board, his responsibilities will include Human Resources and Employee Development.
"We are particularly pleased that we were able to appoint long-time employees from the ZEISS Group to these positions. This will ensure that we can continue driving our current strategy. The Supervisory Board would like to thank Dr. Christian Müller for his excellent work over the past nine years and wishes Mr. Wehmer and Mr. de Cler much success with their new positions," said Prof. Dr. Michael Kaschke, Chairman of the Supervisory Board of Carl Zeiss Meditec AG.
Dr. Christian Müller has been CFO and Member of the Management Board of Carl Zeiss Meditec AG since 2009. He is responsible for Finance and Controlling, Investor Relations, and Legal and Taxes. He also oversees Service, Quality Management and Regulatory Affairs. Dr. Müller joined the ZEISS Group in 2002 as Vice-President of Corporate Auditing and Risk Management. In 2006, he transferred to Carl Zeiss Meditec AG where he headed the newly created Surgical Ophthalmology strategic business unit with sites in Germany, France and Scotland. He previously served as head of finance at Degussa AG starting in 1999 and, from 1997, as department head for auditing and risk management at VIAG AG. He began his professional career at the auditing company C&L Deutsche Revision in 1992. Dr. Christian Müller holds a degree in business administration and completed his Ph.D. at the University of Frankfurt am Main in 1996.
Justus Felix Wehmer has served as Co-Head of the Microscopy business group and Managing Director of Carl Zeiss Microscopy GmbH since 2015. He headed Carl Zeiss Jena GmbH beginning in 2013. Prior to this, he was vice-president of finance and strategy and general manager at NXP Semiconductors Germany GmbH in Hamburg. He had already worked at ZEISS in the period from 2002 to 2012 – initially as Senior Vice-President for Finance at the Industrial Metrology business group and, from 2007, he held the same position at the Semiconductor Manufacturing Technology business group. Justus Felix Wehmer studied business administration at the Academy of Business and Administration in Essen and was awarded an MBA by the London Business School in 1995.
Jan Willem de Cler has been Head of Surgical Ophthalmology at Carl Zeiss Meditec AG since 2010. He came to ZEISS in 2004 as Managing Director of the Benelux sales and service company. He also served as Managing Director of the sales and service company in France and of France Chirurgie Instrumentation (FCI). In January 2014, he was responsible for the strategic acquisition of the American company Aaren Scientific Inc., which enabled the further globalization of the surgical ophthalmology business. Jan Willem de Cler studied marketing and management at Nijenrode University in the Netherlands and earned an MBA in international business from the University of Oregon, USA. After holding different positions at General Electric and GE Medical Systems, he became co-founder and head of sales & marketing for the startup Global Healthcare Exchange Europe.
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,000 employees worldwide, the Group generated revenue of €1,189.9m in fiscal year 2016/17 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med